Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 10:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 8,272 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Age Clear all

Conditions: Neovascular Age-Related Macular Degeneration (nAMD)
Interventions: KHK4951, Aflibercept Injection; Drug
Lead sponsor: Kyowa Kirin Co., Ltd.; Industry
Eligibility: 50 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 38
States / cities: Mesa, Arizona • Tucson, Arizona • Arcadia, California + 34 more

Conditions: Age-related Macular Degeneration, Choroidal Neovascular Age-related Macular Degeneration
Interventions: Not listed
Lead sponsor: Sequenom, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Encinitas, California

Conditions: COVID-19
Interventions: Assessing the impact of COVID-19; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Timeline: 2020
U.S. locations: 1
States / cities: Fayetteville, Arkansas

Conditions: Lipedema
Interventions: Not listed
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Gram-negative Bacterial Infections, Hospital Acquired Bacterial Pneumonia (HABP), Complicated Urinary Tract Infection (cUTI), Ventilator Associated Bacterial Pneumonia (VABP)
Interventions: Cefiderocol, Standard of Care; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Iowa City, Iowa • Fort Worth, Texas

Conditions: Severe Hemophilia A, Moderate Hemophilia A
Interventions: Emicizumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 13 Years to 69 Years
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Miami, Florida • Oklahoma City, Oklahoma

Conditions: Metabolic Syndrome
Interventions: aged garlic extract, placebo; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 40 Years to 65 Years
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Torrance, California

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Observation of Ocrelizumab as Treatment in RRMS Patients; Other
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Vascular Aging
Interventions: Placebo, High-dose trehalose; Drug
Lead sponsor: University of Colorado, Boulder; Other
Eligibility: 50 Years to 79 Years
Enrollment: 110 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Prader Willi Syndrome, Childhood Obesity
Interventions: Active Play at Home; Behavioral
Lead sponsor: California State University, Fullerton; Other
Eligibility: 8 Years to 15 Years
Enrollment: 115 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Fullerton, California • Gainesville, Florida

Conditions: Treatment of Bleeding, Prophylaxis of Bleeding, Hemophilia A, Children
Interventions: Damoctocog alfa pegol (Jivi, BAY94-9027); Biological
Lead sponsor: Bayer; Industry
Eligibility: 7 Years to 11 Years · Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Influenza
Interventions: Investigational H7N1 vaccine GSK2789869A, Investigational H7N1 vaccine GSK2789868A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 21 Years to 64 Years
Enrollment: 427 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 6
States / cities: Miami, Florida • Stockbridge, Georgia • Las Vegas, Nevada + 3 more

Conditions: Immunosuppression
Interventions: Microsampling; Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 17 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Geographic Atrophy, Age Related Macular Degeneration, AMD, Atrophy, Geographic
Interventions: ALK-001 oral capsule, Placebo oral capsule; Drug
Lead sponsor: Alkeus Pharmaceuticals, Inc.; Industry
Eligibility: 60 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 24
States / cities: Phoenix, Arizona • Beverly Hills, California • Lakewood, Colorado + 20 more

Conditions: Alzheimer's Disease
Interventions: Not listed
Lead sponsor: Neuronetrix, Inc.; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Vaping, Cessation, Tobacco
Interventions: This is Quitting, Assessment only control, Waitlist control; Behavioral · Other
Lead sponsor: Truth Initiative; Other
Eligibility: 13 Years to 17 Years
Enrollment: 1,681 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Heart Failure, Decompensated Heart Failure
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Rheumatic Disease
Interventions: Not listed
Lead sponsor: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); NIH
Eligibility: 18 Years to 90 Years
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: GW642444, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 5
States / cities: Cypress, California • Huntington Beach, California • Denver, Colorado + 2 more

Conditions: Influenza
Interventions: Influenza Vaccine; Biological
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 64 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Autism Spectrum Disorder, Nonverbal Communication
Interventions: Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD; Behavioral
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 3 Years to 6 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Hypothyroidism
Interventions: Iodinated contrast agents; Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 3 Years
Enrollment: 2,320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Oakland, California

Conditions: Influenza
Interventions: AVX502, Placebo; Biological
Lead sponsor: AlphaVax, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Raman Spectroscopy, Children, Only
Interventions: Feeding trial; Other
Lead sponsor: Utah State University; Other
Eligibility: 5 Years to 18 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Logan, Utah

Search by objective public record fields.

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

Association of Macular Pigment Optical Density (MPOD) and Genetic Variants in Complement Factor H in Subjects With Choroidal Neovascular (CNV)

Impact of COVID-19 on Marshallese Communities in the U.S.

Visualizing Vascular Mechanisms of Lipedema

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Pediatric Participants

A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

Effect of Aged Garlic Extract on Atherosclerosis

Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis

Oral Trehalose Therapy to Reverse Arterial Aging in Middle-Aged and Older Adults

Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood

Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 21 to 64 Years of Age

Microsampling Assays for Immunosuppressive Drugs in Children

Phase 2/3 Study of ALK-001 in Geographic Atrophy

Evaluation of the COGNISION(TM) System as an Event-related Potential (ERP) Collection System.

Text Message Quit Vaping Intervention for Adolescents

Monocyte Phenotypic Changes in Heart Failure

Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease

Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects

Bone Marrow and Peripheral Blood Immune Responses Study

Exploring Predictors of Response to a Peer-Mediated Intervention for Preschoolers With ASD

Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States

A Safety and Immunogenicity Trial in Adults 65 Years of Age or Over to Prevent Influenza

The Effect of a Nutrient Dense Food on the Skin CarotenoidLevels of School Age Children